Briody H, Duong D, Yeoh SW, Hodgson R, Yong TL, Hannah A, et al. Radioembolization for Treatment of Hepatocellular Carcinoma: Current Evidence and Patterns of Utilization. J Vasc Int Radiol 2023;34(7):1200-13.
DOI: 10.1016/j.jvir.2023.03.020
Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin Molecular Hepatol 2017;23(2):109-14.
DOI: 10.3350/cmh.2017.0004
Anbari Y, Veerman FE, Keane G, Braat AJAT, Smits MLJ, Bruijnen RCG, et al. Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer. J Interv Med 2023;6(4);153-9.
DOI: 10.1016/j.jimed.2023.09.001
Busse NC, Al-Ghazi MSAL, Abi-Jaoudeh N, Álvarez D, Ayan AS, Chen E, et al. AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization. JACMP 2024;25(2):e14157.
DOI: 10.1002/acm2.14157
Maciak M, Konior M, Wawszczak D, Majewska A, Brodaczewska K, Piasecki P, et al. Physical properties and biological impact of 90Y microspheres prepared by sol-gel method for liver radioembolization. Radiation Physics and Chemistry 2023;202.
DOI: 10.1016/j.radphyschem.2022.110506
Villalobos A, Soliman MM, Majdalany BS, Schuster DM, Galt J, Bercu ZL, et al. Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. Seminars in Interv Radiol 2020;37(5):543-54.
DOI: 10.1055/s-0040-1720954
Chansangrat J, Gadani S. Radioembolization for hepatocellular carcinoma: updated strategies and evolving clinical applications. Hepatoma Res 2024;10:49.
DOI: 10.20517/2394-5079.2024.92
Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. The British J Radiol 2016;89(1062):20150943.
DOI: 10.1259/bjr.20150943
Drescher R, Köhler A, Seifert P, Aschenbach R, Ernst T, Rauchfuß F, et al. Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer. Biomedicines 2023;11(7):1831.
DOI: 10.3390/biomedicines11071831
Stella M, Braat A, Van Rooij R, De Jong H, Lam M. Holmium-166 Radioembolization: Current Status and Future Prospective. Cardio Vasc Interv Radiol 2022;45:1634-45.
DOI: 10.1007/s00270-022-03187-y
Braat A, Kwekkeboom DJ, Kam BLR, Teunissen JJM, De Herder WW, Dreijerink KMA, et al. Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE.; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018;18:84.
DOI: 10.1186/s12876-018-0817-8
Prince JF, Van den Bosch M, Nijsen JFW, Smits MLJ, Van den Hoven AF, Nikolakopoulos S, et al. Efficacy of Radioembolization with (166)Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med 2018;59:582-8.
DOI: 10.2967/jnumed.117.197194
Smits ML, Nijsen JF, Van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): A phase 1, dose-escalation study. Lancet Oncol 2012;13:1025-34.
DOI: 10.1016/S1470-2045(12)70334-0
Van Roekel C, Van den Hoven AF, Bastiaannet R, Bruijnen RCG, Braat A, De Keizer B, et al. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. Eur J Nucl Med Mol Imaging 2021;48:1658-68.
DOI: 10.1007/s00259-020-05079-0
Reinders MTM, Van Erpecum KJ, Smits MLJ, Braat A, Bruijne J, Bruijnen R, et al. Safety and Efficacy of (166)Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. J Nucl Med 2022;63:1891-8.
DOI: 10.2967/jnumed.122.263823
Choi JW, Kim HC. Radioembolization for hepatocellular carcinoma: what clinicians need to know. J Liver Cancer 2022;22(1):4-13.
DOI: 10.17998/jlc.2022.01.16
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T, et al; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6(1):17-29.
DOI: 10.1016/S2468-1253(20)30290-9
Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, et al. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology 2022;303(3):699-710.
DOI: 10.1148/radiol.211806
Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma. Gastroenterology 2016;151(6):1155-63.e2.
DOI: 10.1053/j.gastro.2016.08.029
Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68(4):724-32.
DOI: 10.1016/j.jhep.2017.12.026
Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.
DOI: 10.1053/j.gastro.2010.10.049
Hao K, Paik AJ, Han LH, Makary MS. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J Radiol 2024;16(10):512-27.
DOI: 10.4329/wjr.v16.i10.512
Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. Radiology 2017;283(3):895-905.
DOI: 10.1148/radiol.2016160718
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England J Med 2020;382(20):1894-905.
DOI: 10.1056/NEJMoa1915745
Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, De Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019);71(6):1164-74.
DOI: 10.1016/j.jhep.2019.08.006
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma. J Clin Oncol 2018;36(19):1913-21.
DOI: 10.1200/JCO.2017.76.0892
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18(12):1624-36.
DOI: 10.1016/S1470-2045(17)30683-6
Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol (London, England) 2020;16(1):4315-25.
DOI: 10.2217/fon-2019-0658
Hermann AL, Dieudonné A, Ronot M, Sánchez M, Pereira H, Chatellier G, et al. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study. Radiology 2020;296(3):673-84.
DOI: 10.1148/radiol.2020191606
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, García-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93.
DOI: 10.1016/j.jhep.2021.11.018
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182-236.
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6(12):1025-35.
DOI: 10.1016/S2468-1253(21)00305-8
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England J Med 2020;382(20):1894-905.
DOI: 10.1056/NEJMoa1915745
Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 2022;7(9):843-50.
DOI: 10.1016/S2468-1253(22)00091-7
Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, et al. Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Physics 2018;101(2):358-65.
DOI: 10.1016/j.ijrobp.2018.01.116
Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (Baltimore, Md.) 2014;60(1):192-201.
Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, et al. Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation Study. J Vasc Int Radiol 2021;32(4):518-526.e1.
DOI: 10.1016/j.jvir.2020.12.019
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology (Baltimore, Md.) 2021;74(5):2342-52.
Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodríguez-Fraile M, Rodríguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology (Baltimore, Md.) 2013;57(3):1078-87.
Van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2016;34(15):1723-31.
DOI: 10.1200/JCO.2015.66.1181
Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, et al., & Society of Interventional Radiology Standards of Practice Committee. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol 2017;28(1):1-15.
DOI: 10.1016/j.jvir.2016.09.024
Su YK, Mackey RV, Riaz A, Gates VL, Benson AB 3rd, Miller FH, et al. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. J Vasc Interv Radiol 2017;28(11):1520-6.
DOI: 10.1016/j.jvir.2017.05.011
Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, et al. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol 2018;29(6):858-65.
DOI: 10.1016/j.jvir.2018.02.002
Sangro B, Martínez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology (Baltimore, Md.) 2017;66(3):969-82.
Buettner S, Braat AJAT, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, et al. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. J Vasc Interv Radiol 2020;31(7):1035-43.e2.
DOI: 10.1016/j.jvir.2020.02.008
Kim HC, Joo I, Lee M, Chung JW. Benign Biliary Stricture after Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31(12):2014-21.
DOI: 10.1016/j.jvir.2020.07.024
Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012;23(1):96-105.
DOI: 10.1016/j.jvir.2011.09.028
Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Seminars in Interventional Radiology 2011;28(2):240-5.
DOI: 10.1055/s-0031-1280673
Lam MGEH, Banerjee S, Louie JD, Abdelmaksoud MHK, Iagaru AH, Ennen RE, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Interv Radiol 2013;36(6):1536-47.
DOI: 10.1007/s00270-013-0579-1
McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Rad Oncol Biol Physics 1995;31(5):1187-203.
DOI: 10.1016/0360-3016(94)00429-O
Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 2004;71(2):175-81.
DOI: 10.1016/j.radonc.2004.02.005
Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008;31(5):431-8.
DOI: 10.1097/COC.0b013e318168ef65
Kim HC, Kim GM. Radiation pneumonitis following Yttrium-90 radioembolization: A Korean multicenter study. Frontiers in Oncol 2023;13:977160.
DOI: 10.3389/fonc.2023.977160
Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplantation 2009;9(8):1920-8.
DOI: 10.1111/j.1600-6143.2009.02695.x
Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, et al. Downstaging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology 2021;161(5):1502-12.
DOI: 10.1053/j.gastro.2021.07.033
Número de descargas:
41
Número de visitas:
8
Citas:
0
